Brind.

Ultragenyx Pharmaceutical and Fortress Biotech are seeking FDA approval for gene therapy candidates.

1 report, 1 independent Updated Jul 10
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Ultragenyx Pharmaceutical and Fortress Biotech are seeking FDA approval for gene therapy candidates.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • ZacksUltragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains? Ultragenyx RARE shares ended the last trading session 5.1% higher at $41.44. The jump came on an impressive volume with a higher